People
Olivier is a partner in King & Spalding’s Paris office advising on tax issues related to domestic and cross-border transactions involving mergers, acquisitions and group restructuring operations with a specific focus on the pharmaceutical industry and, more generally, the healthcare, new technologies and finance sectors.
He also advises company directors and key managers in the tax structuring of their professional and personal assets. His expertise also includes tax litigation and criminal proceedings relating to tax offences.
Master in Business and Tax Law, University Paris Dauphine
D.E.S.S., University Paris II Panthéon-Assas
LL.M., Ludwig Maximilian University of Munich
Paris
French
German
April 10, 2026
Leveraged buyout of Vachon Group by Apax, through its portfolio company S&W Partners Group
March 30, 2026
K&S advises Chequers Capital on the majority leveraged buyout of ASERTI Group
Advised Eurofins Scientific on the €230 m acquisition of Biomnis
May 22, 2025
Régime des impatriés et carried interest
February 5, 2024
Chinese Medical Device Group Prevails in French Patent Case
April 10, 2026
Leveraged buyout of Vachon Group by Apax, through its portfolio company S&W Partners Group
March 30, 2026
K&S advises Chequers Capital on the majority leveraged buyout of ASERTI Group
Advised Eurofins Scientific on the €230 m acquisition of Biomnis
May 22, 2025
Régime des impatriés et carried interest
February 5, 2024
Chinese Medical Device Group Prevails in French Patent Case
April 10, 2026
Leveraged buyout of Vachon Group by Apax, through its portfolio company S&W Partners Group
March 30, 2026
K&S advises Chequers Capital on the majority leveraged buyout of ASERTI Group
Master in Business and Tax Law, University Paris Dauphine
D.E.S.S., University Paris II Panthéon-Assas
LL.M., Ludwig Maximilian University of Munich
Paris
French
German